BRPI0412444B8 - fração de quil a com baixa toxidez e seu uso - Google Patents

fração de quil a com baixa toxidez e seu uso

Info

Publication number
BRPI0412444B8
BRPI0412444B8 BRPI0412444A BRPI0412444A BRPI0412444B8 BR PI0412444 B8 BRPI0412444 B8 BR PI0412444B8 BR PI0412444 A BRPI0412444 A BR PI0412444A BR PI0412444 A BRPI0412444 A BR PI0412444A BR PI0412444 B8 BRPI0412444 B8 BR PI0412444B8
Authority
BR
Brazil
Prior art keywords
adjuvant
fraction
low toxicity
lps
derivatives
Prior art date
Application number
BRPI0412444A
Other languages
English (en)
Inventor
Jill Ekström
Bengtsson Karin Lövgren
Bror Morein
Katarina Ranlund
Original Assignee
Isconova Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isconova Ab filed Critical Isconova Ab
Publication of BRPI0412444A publication Critical patent/BRPI0412444A/pt
Publication of BRPI0412444B1 publication Critical patent/BRPI0412444B1/pt
Publication of BRPI0412444B8 publication Critical patent/BRPI0412444B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

"fração de quil a com baixa toxidez e seu uso". a invenção refere-se ao uso da fração a de quil a em conjunto com pelo menos um outro adjuvante para a preparação de uma composição adjuvante, em que os componentes adjuvantes incluídos atuam sinergicamente para aumentar o nível de resposta imune e apresentam atividade imuno-moduladora sinérgica sobre os antígenos ou imunógenos co-administrados. o pelo menos outro adjuvante pode ser escolhido de saponinas, de ocorrência natural, moléculas de saponina sintéticas ou semi-sintéticas, por exemplo, saponinas e frações de saponina de quil a, esqueleto de parede celular, polímeros em bloco, tdm, lipopeptídeos, lps e derivados de lps, lipídeo a de diferentes espécies de bactérias e derivados deste, por exemplo, monofosforil lipídeo a, variantes de cpg, ct e lt ou frações (derivados destes.
BRPI0412444A 2003-07-07 2004-07-07 fração de quil a com baixa toxidez e seu uso BRPI0412444B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301998A SE0301998D0 (sv) 2003-07-07 2003-07-07 Quil A fraction with low toxicity and use thereof
PCT/SE2004/001038 WO2005002620A1 (en) 2003-07-07 2004-07-07 Quil a fraction with low toxicity and use thereof

Publications (3)

Publication Number Publication Date
BRPI0412444A BRPI0412444A (pt) 2006-09-19
BRPI0412444B1 BRPI0412444B1 (pt) 2016-06-14
BRPI0412444B8 true BRPI0412444B8 (pt) 2021-05-25

Family

ID=27731119

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412444A BRPI0412444B8 (pt) 2003-07-07 2004-07-07 fração de quil a com baixa toxidez e seu uso

Country Status (15)

Country Link
US (8) US8821881B2 (pt)
EP (1) EP1648505B1 (pt)
JP (1) JP4731475B2 (pt)
AT (1) ATE442164T1 (pt)
AU (1) AU2004254152B2 (pt)
BR (1) BRPI0412444B8 (pt)
CA (1) CA2529363C (pt)
DE (1) DE602004023089D1 (pt)
DK (1) DK1648505T3 (pt)
ES (1) ES2331952T3 (pt)
NZ (1) NZ544299A (pt)
PL (1) PL1648505T3 (pt)
SE (1) SE0301998D0 (pt)
WO (1) WO2005002620A1 (pt)
ZA (1) ZA200600151B (pt)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049302B1 (en) * 1998-08-10 2006-05-23 Antigenics Inc. Compositions of CPG and saponin adjuvants and uses thereof
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
US8007806B2 (en) 2005-01-20 2011-08-30 Isconova Ab Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
EP1764369A1 (de) * 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
EP2382987A1 (en) 2006-03-24 2011-11-02 Novartis Vaccines and Diagnostics GmbH Storage of influenza vaccines without refrigeration
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
WO2008031878A1 (en) * 2006-09-15 2008-03-20 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH A composition for therapy and/or for prophylaxis of hbv-infections and hbv-mediated diseases
EP1902727A1 (de) * 2006-09-22 2008-03-26 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
CN101563090B (zh) * 2006-11-20 2013-01-02 杜科姆公司 包含南美皂皮树皂苷的含脂质颗粒用于治疗癌症的用途
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
JP5659332B2 (ja) * 2008-06-27 2015-01-28 ゾエティス・エルエルシー 新規なアジュバント組成物
CN102470168A (zh) * 2009-07-10 2012-05-23 伊斯克诺瓦公司 新组合物
CN103118702A (zh) 2010-09-20 2013-05-22 克鲁塞尔荷兰公司 活动性结核病的治疗性接种
TR201808733T4 (tr) 2011-10-03 2018-07-23 Mx Adjuvac Ab Kanser tedavisini ve gıda ile ilgili bileşikleri içeren tıp alanlarında amfipatik veya hidrofobik moleküller için taşıyıcı olarak nano-parçacıklar, preparasyon için proses ve bunların kullanımı.
SG11201402633UA (en) 2011-11-28 2014-09-26 Crucell Holland Bv Influenza virus vaccines and uses thereof
CA2864956C (en) 2012-03-12 2021-11-09 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CN104334188B (zh) 2012-03-22 2016-08-24 克鲁塞尔荷兰公司 抗rsv疫苗
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
EP2953638B1 (en) 2013-02-07 2023-07-05 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
BR112015021523A8 (pt) 2013-03-08 2021-06-29 Crucell Holland Bv composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
AU2014259474B2 (en) 2013-04-25 2018-09-13 Janssen Vaccines & Prevention B.V. Stabilized soluble prefusion RSV F polypeptides
BR112015029635B1 (pt) 2013-05-30 2023-05-02 Janssen Vaccines & Prevention B.V Polipeptídeo do domínio de haste da hemaglutinina da gripe e composição
MY171210A (en) 2013-06-17 2019-10-02 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f polypeptides
WO2015000831A1 (en) 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
WO2015000832A1 (en) 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
CA2924526A1 (en) 2013-09-19 2015-03-26 Paul Joseph Dominowski Water-in-oil emulsions comprising immunostimulatory oligonucleotides
DE102014005771A1 (de) 2014-04-23 2015-10-29 Clariant International Ltd. Verwendung von wässrigen driftreduzierenden Zusammensetzungen
US10111944B2 (en) 2014-07-10 2018-10-30 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
MA40902B1 (fr) 2014-11-04 2018-12-31 Janssen Vaccines & Prevention Bv Vaccins hpv16 thérapeutiques
AR103427A1 (es) 2015-01-16 2017-05-10 Zoetis Services Llc Vacuna contra la fiebre aftosa
EP3283634B1 (en) 2015-04-14 2019-05-22 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
WO2017005844A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
CN107847581B (zh) 2015-07-07 2022-03-22 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
WO2017029360A1 (en) 2015-08-20 2017-02-23 Janssen Vaccines & Prevention B.V. Therapeutic hpv18 vaccines
AU2016316723B2 (en) 2015-09-02 2021-03-25 Janssen Vaccines & Prevention B.V. Stabilized viral class I fusion proteins
RU2730625C2 (ru) 2015-09-03 2020-08-24 Новавакс, Инк. Вакцинные композиции, характеризующиеся улучшенной стабильностью и иммуногенностью
KR102136678B1 (ko) 2015-12-23 2020-07-22 화이자 인코포레이티드 Rsv f 단백질 돌연변이체
WO2017174564A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
IL262108B2 (en) 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V Soluble pre-fusion rsv f proteins are stabilized
US10517944B2 (en) 2016-05-02 2019-12-31 Janssen Vaccines & Prevention B.V. Therapeutic HPV vaccine combinations
DE102016207877A1 (de) 2016-05-09 2017-11-09 Clariant International Ltd Stabilisatoren für Silikatfarben
KR102573534B1 (ko) 2016-05-12 2023-08-31 얀센 백신스 앤드 프리벤션 비.브이. 강력하고 균형 잡힌 양방향성 프로모터
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
WO2017207480A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
US11001858B2 (en) 2016-06-20 2021-05-11 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
CN109906411B (zh) 2016-11-04 2022-12-27 卡博特公司 含结晶聚酯和有机硅的纳米复合物
WO2018146205A1 (en) 2017-02-09 2018-08-16 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
CN111148509A (zh) 2017-07-24 2020-05-12 诺瓦瓦克斯股份有限公司 治疗呼吸系统疾病的方法和组合物
MX2020002876A (es) 2017-09-15 2020-07-22 Janssen Vaccines & Prevention Bv Metodo para la induccion segura de inmunidad contra el vsr.
PT3743106T (pt) 2018-01-23 2022-08-24 Janssen Vaccines & Prevention Bv Vacinas contra o vírus da influenza e suas utilizações
IL305911B1 (en) 2018-03-19 2024-09-01 Novavax Inc Multifunctional nanoparticle vaccines for influenza
GB201807303D0 (en) 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
KR20210016562A (ko) 2018-05-23 2021-02-16 에이디씨 테라퓨틱스 에스에이 분자 애쥬번트
EA202191355A1 (ru) 2018-11-13 2021-09-20 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные f-белки rsv до слияния
WO2020216844A1 (en) 2019-04-25 2020-10-29 Janssen Vaccines & Prevention B.V. Recombinant influenza antigens
KR20220008875A (ko) 2019-05-15 2022-01-21 얀센 백신스 앤드 프리벤션 비.브이. 계절성 인플루엔자 백신과 아데노바이러스 기반 호흡기 세포융합 바이러스 백신의 공동투여
EA202193119A1 (ru) 2019-05-15 2022-02-18 Янссен Вэксинс Энд Превеншн Б.В. Профилактическое лечение инфекции, вызванной респираторно-синцитиальным вирусом, вакциной на основе аденовируса
AU2020342463A1 (en) 2019-09-05 2022-03-24 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US20230075527A1 (en) 2020-01-31 2023-03-09 Janssen Pharmaceuticals, Inc Compositions and Methods for Preventing and Treating Coronavirus Infection - Sars-Cov-2 Vaccines
MX2022014162A (es) 2020-05-11 2023-02-23 Janssen Pharmaceuticals Inc Proteínas de fusión de la proteína de la espícula del coronavirus estabilizadas.
CN116096409A (zh) 2020-05-11 2023-05-09 杨森制药公司 编码稳定化的冠状病毒刺突蛋白的rna复制子
AU2021272741A1 (en) 2020-05-11 2023-02-02 Janssen Pharmaceuticals, Inc. SARS-CoV-2 vaccines
BR112022026408A2 (pt) 2020-06-29 2023-01-17 Janssen Vaccines & Prevention Bv Combinação vacinal contra infecção pelo vírus sincicial respiratório
MX2023000373A (es) 2020-07-06 2023-02-13 Janssen Pharmaceuticals Inc Proteinas de fusion de proteinas de la espicula de coronavirus estabilizadas.
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
JP2024509756A (ja) 2021-02-19 2024-03-05 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された融合前ｒｓｖ ｆｂ抗原
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
US20240197859A1 (en) 2021-04-01 2024-06-20 Janssen Vaccines & Prevention B.V. Stabilized Pre-Fusion PIV3 F Proteins
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023110618A1 (en) 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2023196634A2 (en) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2023217988A1 (en) 2022-05-12 2023-11-16 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2024017682A1 (en) 2022-07-18 2024-01-25 Janssen Vaccines & Prevention B.V. Rsv immunogens
WO2024030856A2 (en) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Immunomodulatory proteins and related methods
WO2024061753A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024074584A1 (en) 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
WO2024104947A2 (en) 2022-11-14 2024-05-23 Janssen Vaccines & Prevention B.V. Influenza b virus vaccines and uses thereof
WO2024151583A2 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2024154048A1 (en) 2023-01-18 2024-07-25 Pfizer Inc. Vaccines against respiratory diseases
US20240269263A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
WO2024175579A1 (en) 2023-02-21 2024-08-29 Janssen Vaccines & Prevention B.V. Stabilized trimeric rsv fusion proteins without a heterologous trimerzation domain

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5839376B2 (ja) * 1978-10-30 1983-08-30 富士通株式会社 イオン注入法
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
ES2039229T3 (es) * 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE9600647D0 (sv) * 1996-02-21 1996-02-21 Bror Morein Ny användning
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof

Also Published As

Publication number Publication date
JP2007527386A (ja) 2007-09-27
US20160184427A1 (en) 2016-06-30
WO2005002620A1 (en) 2005-01-13
PL1648505T3 (pl) 2010-02-26
BRPI0412444A (pt) 2006-09-19
DE602004023089D1 (de) 2009-10-22
EP1648505B1 (en) 2009-09-09
US20240024468A1 (en) 2024-01-25
ATE442164T1 (de) 2009-09-15
US20220241408A1 (en) 2022-08-04
US20060239963A1 (en) 2006-10-26
EP1648505A1 (en) 2006-04-26
NZ544299A (en) 2009-03-31
US20200345840A1 (en) 2020-11-05
CA2529363C (en) 2013-04-02
CA2529363A1 (en) 2005-01-13
US20140335049A1 (en) 2014-11-13
US20180369368A1 (en) 2018-12-27
ZA200600151B (en) 2007-01-31
DK1648505T3 (da) 2009-12-21
SE0301998D0 (sv) 2003-07-07
JP4731475B2 (ja) 2011-07-27
AU2004254152A1 (en) 2005-01-13
US20150320858A1 (en) 2015-11-12
US8821881B2 (en) 2014-09-02
AU2004254152B2 (en) 2009-10-29
ES2331952T3 (es) 2010-01-21
BRPI0412444B1 (pt) 2016-06-14

Similar Documents

Publication Publication Date Title
BRPI0412444B8 (pt) fração de quil a com baixa toxidez e seu uso
BRPI0619795B8 (pt) composição imunogênica, composição adjuvante, e, uso de uma composição imunogênica e um adjuvante
BRPI0515316A (pt) compostos de imidazoquinolina
NO20061912L (no) Vaksinesammensetninger omfattende et interleukin 18 og saponin adjuvant system
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
BR0311777A (pt) Composição de vesìcula meningocócica multivalente, vacina para o tratamento de doença neisserial, métodos para fabricação de composição de vesìcula meningocócica multivalente e para prevenção ou tratamento de doença neisserial, e, uso de uma quantidade imunologicamente eficaz da vacina
BR0312472A (pt) Prepração de uma composição compreendendo uma mistura de complexos de iscom e uso da dita composição
BRPI0717183B8 (pt) exendina ou análogo de exendina modificada por peg, composição e seu uso
ES2135370T1 (es) Uso de un extracto de hojas de olea europea como antirradical.
BRPI0507266A (pt) massas de moldagem termoplásticas, uso das mesmas, e, fibras, folhas, ou moldagem de qualquer tipo
BRPI0510396A (pt) vacina compreendendo um pestivìrus atenuado
BRPI0510430A (pt) composições e métodos para vacinação mucosal
BRPI0914536A8 (pt) Tiadiazoliloxifenilamidinas, processo para sua preparação e seus usos, composição e processo para combater microorganismos indesejáveis, e semente resistente a microorganismos indesejáveis
BRPI0511026A (pt) uso de um los neisserial, e, composição
BRPI1009842B8 (pt) uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas
CL2009000757A1 (es) Compuestos derivados de 6,8,2´-tris-(isobut-2-en-1-il)-diosmetina; procedimientos para su elaboracion; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades venosas cronicas, sindrome post-trombotico, complicaciones vasculares ligadas a la diabetes, entre otras.
CO6220833A2 (es) Inmuno reguladores preparaciones y composiciones que incluyen los inmuno-reguladores pruebas para evaluar la actividad de los inmuno-reguladores y preparaciones y composiciones que incluyen los mismos y metodos
BRPI0507111A (pt) processo para a preparação de um composto e seus adutos de mannich, composição, concentrado aditivo para combustìveis, e, usos de uma composição e de pelo menos um composto
NO20070746L (no) Anvendelse av fosfaterte alkanoler som dispergente , emulgatorer, hydrotroper, fuktmidler og kompatabilitetsstoffer i blandinger for jordbruket.
BRPI0309421A8 (pt) Método de preparar um gênero alimentício e composição para tratar ou prevenir hipercolesterolemia
BR112022011445A2 (pt) Composição imunoestimuladora e uso da mesma
ES2140837T3 (es) Adyuvante a base de saponina de madera de panama y formulacion de vacuna que lo contiene.
BR112012006872A2 (pt) composição, promotor de lipólise oral, inibidor de enzima de conversão de angiotensina oral, e, alimento ou bebida
CL2004000535A1 (es) Composicion farmaceutica que comprende rapamicina o un derivado de rapamicina y pimecrolimus; y su uso para el tratamiento de enfermedad inflamatoria del intestino.
BRPI0516811A (pt) compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/06/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/07/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF